Companies › Eli Lilly › Cash and equivalents

Eli Lilly cash and cash equivalents, 2008–2025

Eli Lilly reported cash and cash equivalents of $7.27 billion at the end of the fiscal year ended Dec. 31, 2025, up 122.4% from $3.27 billion the year before, according to its Form 10-K.

$7.27Blatest fiscal year (ended Dec. 31, 2025)
+122.4%change from the year before
$7.32Bhighest year shown (2018)
2008: $5.50B ’08 2009: $4.46B 2010: $5.99B ’10 2011: $5.92B 2012: $4.02B ’12 2013: $3.83B 2014: $3.87B ’14 2015: $3.67B 2016: $4.58B ’16 2017: $6.54B 2018: $7.32B ’18 2019: $2.34B 2020: $3.66B ’20 2021: $3.82B 2022: $2.07B ’22 2023: $2.82B 2024: $3.27B ’24 2025: $7.27B ’25

Fiscal years labeled by the year in which they ended. Bars drawn from the table below.

Eli Lilly cash and cash equivalents by fiscal year

Fiscal year endedCash and equivalentsChangeFiling
Dec. 31, 2025 $7.27B +122.4% 10-K (2026) ↗
Dec. 31, 2024 $3.27B +15.9% 10-K (2026) ↗
Dec. 31, 2023 $2.82B +36.4% 10-K (2025) ↗
Dec. 31, 2022 $2.07B −45.9% 10-K (2024) ↗
Dec. 31, 2021 $3.82B +4.4% 10-K (2023) ↗
Dec. 31, 2020 $3.66B +56.5% 10-K (2022) ↗
Dec. 31, 2019 $2.34B −68.1% 10-K (2021) ↗
Dec. 31, 2018 $7.32B +12.0% 10-K (2020) ↗
Dec. 31, 2017 $6.54B +42.6% 10-K (2019) ↗
Dec. 31, 2016 $4.58B +25.0% 10-K (2019) ↗
Dec. 31, 2015 $3.67B −5.3% 10-K (2019) ↗
Dec. 31, 2014 $3.87B +1.1% 10-K (2018) ↗
Dec. 31, 2013 $3.83B −4.7% 10-K (2017) ↗
Dec. 31, 2012 $4.02B −32.1% 10-K (2016) ↗
Dec. 31, 2011 $5.92B −1.2% 10-K (2015) ↗
Dec. 31, 2010 $5.99B +34.3% 10-K (2014) ↗
Dec. 31, 2009 $4.46B −18.8% 10-K (2013) ↗
Dec. 31, 2008 $5.50B — 10-K (2012) ↗

Other Eli Lilly financials

RevenueNet incomeDiluted EPSR&D expenseOperating cash flowDividends per shareDiluted sharesTotal assetsStockholders' equity Quarterly results and next earnings date Eli Lilly company hub

FAQ

Q What was Eli Lilly's cash and cash equivalents in its latest fiscal year?

A Eli Lilly reported cash and cash equivalents of $7.27 billion at the end of the fiscal year ended Dec. 31, 2025, up 122.4% from $3.27 billion the year before, according to its Form 10-K.

Q What is Eli Lilly's highest annual cash and cash equivalents on record here?

A $7.32 billion, in the fiscal year ended Dec. 31, 2018, among the fiscal years 2008–2025 reported in its 10-K XBRL data.

Q Where does this cash and cash equivalents data come from?

A From Eli Lilly's annual reports on Form 10-K, as tagged in XBRL and published by the SEC (company facts). Cash and cash equivalents on the balance sheet at fiscal year-end (excluding marketable securities).

Source: Eli Lilly's annual reports on Form 10-K via SEC XBRL company facts, updated Oct. 15, 2026. Cash and cash equivalents on the balance sheet at fiscal year-end (excluding marketable securities). For each year the most recent 10-K that reports it is used, so a figure a company later restated shows the restated value; the filing link shows which report it came from. Change is our arithmetic. Financial data, not investment advice.